Stem Cells Spin (WAR:SCS) Debt-to-Equity : 0.02 (As of Mar. 2025)

View and export this data going back to 2011. Start your Free Trial

What is Stem Cells Spin Debt-to-Equity?

Stem Cells Spin's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was zł0.00 Mil. Stem Cells Spin's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was zł0.10 Mil. Stem Cells Spin's Total Stockholders Equity for the quarter that ended in Mar. 2025 was zł6.77 Mil. Stem Cells Spin's debt to equity for the quarter that ended in Mar. 2025 was 0.02.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Stem Cells Spin's Debt-to-Equity or its related term are showing as below:

WAR:SCS' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.13 Max: 1.33
Current: 0.02

During the past 13 years, the highest Debt-to-Equity Ratio of Stem Cells Spin was 1.33. The lowest was 0.01. And the median was 0.13.

WAR:SCS's Debt-to-Equity is ranked better than
88.89% of 1026 companies
in the Biotechnology industry
Industry Median: 0.145 vs WAR:SCS: 0.02

Stem Cells Spin Debt-to-Equity Historical Data

The historical data trend for Stem Cells Spin's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stem Cells Spin Debt-to-Equity Chart

Stem Cells Spin Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Equity

Get a 7-Day Free Trial

0.13

0.07

0.05

0.01

Stem Cells Spin Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Debt-to-Equity	Get a 7-Day Free Trial															-	-	-	0.01	0.02

Competitive Comparison of Stem Cells Spin's Debt-to-Equity

For the Biotechnology subindustry, Stem Cells Spin's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Stem Cells Spin's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Stem Cells Spin's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Stem Cells Spin's Debt-to-Equity falls into.

Save Embed

;

Save Embed

;

Stem Cells Spin Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Stem Cells Spin's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0.072)	/	6.907
	=	0.01

Stem Cells Spin's Debt to Equity Ratio for the quarter that ended in Mar. 2025 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0.104)	/	6.773
	=	0.02

Stem Cells Spin (WAR:SCS) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Stem Cells Spin Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Stem Cells Spin's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Stem Cells Spin Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stem Cells Spin SA (WAR:SCS) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ulica Konopnickiej 15 b, Wroclaw, POL, 51-141

Website

http://stemcellsspin.com.pl

Stem Cells Spin SA is a biotechnology company. The company is engaged in the development, production, marketing and sale of natural regenerative products for the dermocosmetic and veterinary care markets, as well as applications for the human and veterinary medical industry. Its products include NHAC Biocervin MIC-1, Revitacell, PRS MIC-1 and Velvetyna.